Reduction of chronic rejection of renal allografts by anti-transforming growth factor-β antibody therapy in a rat model

• Published in: American journal of physiology. Renal physiology Vol. 305; no. 2; p. F199
• Main Authors: Guan, Qiunong, Li, Shuyuan, Gao, Sihai, Chen, Huifang, Nguan, Christopher Y C, Du, Caigan
• Format: Journal Article
• Language: English
• Published: United States 15-07-2013
• Subjects: Animals; Antibodies, Monoclonal - therapeutic use; Disease Models, Animal; Down-Regulation - immunology; Fibrosis; Graft Rejection - immunology; Graft Rejection - pathology; Graft Rejection - prevention & control; Kidney Function Tests; Kidney Transplantation - immunology; Male; Rats; Rats, Inbred F344; Rats, Inbred Lew; Transforming Growth Factor beta - immunology; kidney transplant; TGF-β; fibrosis; chronic rejection; antibody therapy
• ISSN: 1522-1466
• DOI: 10.1152/ajprenal.00665.2012

There is no effective treatment for chronic rejection (CR) that largely limits long-term survival of kidney transplants. Transforming growth factor (TGF)-β is a fibrogenic factor for tissue fibrosis. This study was to test the efficacy of an anti-TGF-β antibody in preventing the CR of renal allografts in a preclinical model. Male Lewis rats (RT1¹) were orthotopically transplanted with donor kidneys from male Fischer 344 (RT11v1) rats and were treated with either anti-TGF-β or a control antibody. The CR of renal allografts was assessed by semiquantitative histological analyses, and intragraft cytokines and fibrosis-related genes ware examined by PCR arrays. Compared with the control antibody, anti-TGF-β antibody treatment significantly reduced recipients' proteinuria (P = 0.0002), and CR in renal transplants, which was indicated by the fewer injured renal tubules, glomeruli, and interlobular arterioles or arteries, and by less mononuclear cell infiltration and interstitial fibrosis in the anti-TGF-β antibody-treated group (P < 0.05), but not significantly attenuate the ratios of different infiltrating leukocytes. These pathological changes were associated with downregulation of TGF-β1, TGF-β2, and proinflammatory cytokines, or with upregulation of anti-fibrotic HGF, BMP5, and BMP7. The therapeutic effect of the anti-TGF-β antibody was further confirmed by its prevention of graft dysfunction, indicated by lower levels of serum creatinine and blood urea nitrogen or higher creatinine clearance in anti-TGF-β antibody-treated recipients compared with those in control recipients (P < 0.05). In conclusion, the anti-TGF-β antibody (1D11) treatment significantly reduces CR of renal allografts in rats, suggesting the therapeutic potential of this antibody therapy for treating CR of kidney transplants in patients.